Stocks TelegraphStocks Telegraph
Stock Ideas

VERA Financial Statements and Analysis

NASDAQ : VERA

Vera Therapeutics

$34.99
-0.67-1.88%
At Close 4:00 PM
61.4
BESG ScoreESG Rating

FINANCIAL STATEMENTS

An instrumental part of fundamental analysis is measuring key indicators of an asset, which are the factors that can influence its value and price. However, sometimes investors show more interest in financial statements with other factors to determine whether investing in that company is the right decision. Financial statements of a company include:

  • Balance Sheet
  • Income Statement
  • Cash Flow Statement

Income Statement

A company's income statement helps investors and business owners determine whether the company is profitable or losing money. Profitability is a key factor investors consider before investing in a stock. Income statements provide them with information about a company's profitability over time. The statement also enables them to observe trends in company spending and earnings since it breaks down individual costs and revenues. Income statements also provide details on where a company's money is going when it isn't profitable or its profits fluctuate.

DateJun 30, 2026Mar 31, 2026Sep 30, 2025Jun 30, 2025Mar 31, 2025
reported currencyUSDUSDUSDUSDUSD
calendar year20262026202520252025
periodQ2Q1Q3Q2Q1
revenue00N/A00
cost of revenue0256.00K564.00K563.00K0
gross profit0-256.00K-564.00K-563.00K0
gross profit ratio00000
research and development expenses60.08M86.011M56.344M58.076M41.278M
general and administrative expenses52.41M39.121MN/A21.946M14.58M
selling and marketing expenses00N/A01.336M
selling general and administrative expenses52.41M39.121M27.024M21.946M15.916M
other expenses000-444.00K0
operating expenses112.49M125.132M83.368M79.578M57.194M
cost and expenses112.49M125.132M83.932M80.141M57.194M
interest income5.348M6.355M5.736M6.32M6.906M
interest expense1.848M1.823M1.96M1.874M1.792M
depreciation and amortization132.00K256.00K564.00K563.00K85.00K
ebitda-107.493M-118.953M-77.769M-74.094M-49.817M
ebitda ratio00000
operating income-112.49M-125.132M-83.932M-80.141M-57.194M
operating income ratio00000
total other income expenses net3.017M4.10M3.639M3.61M5.50M
income before tax-109.473M-121.032M-80.293M-76.531M-51.694M
income before tax ratio00000
income tax expense00N/A00
net income-109.473M-121.032M-80.293M-76.531M-51.694M
net income ratio00000
eps-1.52-1.69-1.26-1.20-0.81
eps diluted-1.52-1.69-1.26-1.20-0.81
weighted average shs out71.838M71.477M63.847M63.789M63.672M
weighted average shs out dil71.838M71.477M63.847M63.789M63.672M
Graph

Balance Sheet

Balance sheet summarizes a company's financials and can be used as a basis by investors to determine the value of a company. It shows the value of the stock, as well as the assets and liabilities of the company. A company's balance sheet displays how its assets are put to use and how those assets are financed, based on the liabilities section. Both investors and analysts analyze a company's balance sheet to determine how it allocates its resources.

DateJun 30, 2026Mar 31, 2026Sep 30, 2025Jun 30, 2025Mar 31, 2025
reported currencyUSDUSDUSDUSDUSD
calendar year20262026202520252025
periodQ2Q1Q3Q2Q1
cash and cash equivalents48.876M114.351M57.773M49.121M55.09M
short term investments450.285M482.409M439.616M507.706M534.744M
cash and short term investments499.161M596.76M497.389M556.827M589.834M
net receivables03.908M3.357M4.202M3.586M
inventory00000
other current assets28.332M15.134M5.485M10.325M12.656M
total current assets527.493M615.802M506.231M571.354M606.076M
property plant equipment net1.687M2.751M3.191M3.622M3.977M
goodwill00000
intangible assets00000
goodwill and intangible assets00000
long term investments00000
tax assets00000
other non current assets3.804M3.186M8.081M3.552M114.00K
total non current assets5.491M5.937M11.272M7.174M4.091M
other assets00000
total assets532.984M621.739M517.503M578.528M610.167M
account payables14.573M13.909M17.95M13.157M9.262M
short term debt00473.00K855.00K1.191M
tax payables00000
deferred revenue00000
other current liabilities33.748M31.24M23.457M19.542M11.441M
total current liabilities48.321M45.149M41.88M33.554M21.894M
long term debt75.228M75.029M76.743M76.697M53.274M
deferred revenue non current00000
deferred tax liabilities non current00000
other non current liabilities1.677M1.864M000
total non current liabilities76.905M76.893M76.743M76.697M53.274M
other liabilities00000
capital lease obligations0003.088M3.557M
total liabilities125.226M122.042M118.623M110.251M75.168M
preferred stock00000
common stock72.00K72.00K64.00K64.00K64.00K
retained earnings-991.37M-881.897M-669.768M-589.475M-512.944M
accumulated other comprehensive income loss-403.00K-156.00K881.00K527.00K654.00K
other total stockholders equity1.399B1.382B1.068B1.057B1.047B
total stockholders equity407.758M499.697M398.88M468.277M534.999M
total equity407.758M499.697M398.88M468.277M534.999M
total liabilities and stockholders equity532.984M621.739M517.503M578.528M610.167M
minority interest00000
total investments450.285M482.409M439.616M507.706M534.744M
total debt75.228M75.029M77.216M77.552M54.465M
net debt26.352M-39.322M19.443M28.431M-625.00K
Graph

Cash Flow

A cash flow statement is regarded as a valuable indicator of profitability and the long-term outlook for a company. It assists the company in evaluating whether it has sufficient funds to cover its expenses. Essentially, a cash flow statement represents an organization's financial health. The cash flow statement, which measures the business's ability to operate in the short as well as long term, is broken down into operating, investing, and financing activities.

DateJun 30, 2026Mar 31, 2026Sep 30, 2025Jun 30, 2025Mar 31, 2025
reported currencyUSDUSDUSDUSDUSD
calendar year20262026202520252025
periodQ2Q1Q3Q2Q1
deferred income tax00000
stock based compensation15.863M13.208M9.745M9.472M7.744M
change in working capital-6.443M-13.728M8.686M13.382M-9.438M
accounts receivables00000
inventory00000
accounts payables664.00K-7.966M4.793M3.895M1.597M
other working capital-7.107M-5.762M3.893M9.487M-11.035M
other non cash items-332.00K14.796M-173.00K-1.24M-1.103M
net cash provided by operating activities-100.253M-106.50M-61.906M-54.798M-54.406M
investments in property plant and equipment0-173.00K-133.00K-208.00K-187.00K
acquisitions net00000
purchases of investments-98.056M-210.561M-98.696M-94.728M-89.992M
sales maturities of investments131.03M87.918M168.59M126.061M106.246M
other investing activites-114.00K-15.00M0-2.581M-750.00K
net cash used for investing activites32.86M-137.816M69.761M28.544M15.317M
debt repayment00019.821M0
common stock issued1.918M3.942M0464.00K0
common stock repurchased00000
dividends paid00000
other financing activites00797.00K01.533M
net cash used provided by financing activities1.918M3.942M797.00K20.285M1.533M
effect of forex changes on cash00000
net change in cash-65.475M-240.374M8.652M-5.969M-37.556M
cash at end of period48.876M114.351M57.773M49.121M55.09M
cash at beginning of period114.351M354.725M49.121M55.09M92.646M
operating cashflow-100.253M-106.50M-61.906M-54.798M-54.406M
capital expenditure0-173.00K-133.00K-208.00K-187.00K
free cash flow-100.253M-106.673M-62.039M-55.006M-54.593M
Graph

Frequently Asked Questions

How did Vera Therapeutics, Inc. do last quarter? What was its Total Revenue and Cost of Revenue?
A company's Total Revenue reveals how much money it generates before any expenses or deductions are made. As a result, this metric informs investors/stakeholders how much money the business makes. Tracking and understanding it is essential for evaluating a company's growth. As opposed to revenue, Cost of Revenue is any expenses a business incur to generate revenue. There can be high revenue in a business, but if the costs are high, it won't make a profit and will go out of business when money runs out. Therefore, VERA generated $0.00 in revenue last quarter, while its costs came in at $0.00.
Last quarter, how much Gross Profit did Vera Therapeutics, Inc. report?
A business's Gross Profit is a key indicator of its profitability and financial performance. In other words, it reflects how efficiently a business uses labor, raw materials, and other resources. Vera Therapeutics, Inc. reported a $0.00 Gross Profit for the quarter ended Jun 30, 2026.
Have VERA's Total Operating Expenses and Operating Income been favorable recently?
Operational Expenses represent the costs a company must incur to generate revenue, which is the ultimate goal of a business, whereas Operating Income shows the revenue left after operational direct and indirect costs have been deducted. VERA incurred $112.49M worth of Operating Expenses, while it generated -$112.49M worth of Operating Income.
How much Net Income has VERA posted recently?
The Net Income of a company is one of the factors investors consider when investing in the company. According to recent earnings report from Vera Therapeutics, Inc., the company generated -$109.47M in Net Income. When a company has a history of consistent net income, investors are more likely to invest in it since they know they will get a return.
At the end of the last quarter, how much Cash and Equivalents did Vera Therapeutics, Inc. have?
The amount of Cash and Cash Equivalents is an effective indicator of the financial strength and well-being of a company. An excess cash situation occurs when a company has more cash and cash equivalents than it needs for operating activities. The amount of Cash and Cash Equivalents available to Vera Therapeutics, Inc. as of the end of the last quarter was $48.88M.
What are VERA's Total Net Receivables for the last quarter?
Total Net Receivables are a company's outstanding debts to its customers. Therefore, it refers to the amount that a company expects to collect from its customers. The higher a company's net receivables are, the more confident it is that it can collect money from its debtors. As of the end of the last quarter, VERA had Total Net Receivables of $0.00.
In terms of Total Assets and Current Assets, where did Vera Therapeutics, Inc. stand at?
An asset with an economic value within a year is considered a current asset. Total assets, however, also include long-term fixed assets, intangible assets, and other non-current assets. The current Assets of VERA were $527.49M, while the Total Assets stand at $532.98M.
As of the last quarter, how much Total Debt did Vera Therapeutics, Inc. have?
The total debt of a business refers to how much it borrows. A company's current and long-term liabilities are added together to calculate its Total Debt. A debt ratio may be taken into account on a balance sheet by financial lenders, investors, and business leaders when making informed decisions about future loans or investments. The total amount of VERA's debt was $75.23M at the end of the last quarter.
What were VERA's Total Liabilities during the last reported quarter?
A company's total liabilities are the sum of all debts it is liable for, including any off-balance shee liabilities it may incur. This can be calculated by adding up all short-term and long-term liabilities. In its last quarter, VERA reported total liabilities of $125.23M.
How much did VERA's Working Capital change over the last quarter?
Working Capital Change for VERA was -$6.44M over the last quarter. Working Capital Change refers to the difference between net working capital amounts at the end of one accounting period and the end of another. It tells investors/stakeholders how much the company's cash flow will differ from its Net Income (i.e., after-tax profits). More powerful companies often have positive Change in Working Capital numbers as they have increased control over collecting cash from customers and delaying payments to suppliers.
VERA generated how much cash from operating activities?
An operating cash flow statement usually contains cash from operating activities in the first section. An organization's cash from operating activities refers to the money it takes in and takes out as a result of its regular business operations. VERA generated -$100.25M of Cash from Operating Activities during its recently reported quarter.
What was VERA's latest reported Net Change in Cash?
An increase or decrease in cash and cash equivalent balances within a specified period is considered the net change in cash in a cash flow statement. Furthermore, it takes into account cash changes as a result of investments, financing, and operating activities. VERA reported a -$65.48M Net Change in Cash in the most recent quarter.
logo

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

© 2026 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep

stockstelegraph

Don't have an account?

stockstelegraph

Don't have an account?

stockstelegraph

Already have an account?

stockstelegraph
Smart Screening Tools for Exceptional Returns
stockstelegraph

For just $1, you can unlock ST Grading’s top-rated stocks that consistently beat the market. Our AI-powered Smart Screener finds winning trades in seconds, helping you uncover hidden opportunities before others do.

Ready to Win Big?

Try Now for Just $1!
stockstelegraph